|
1
|
Estey E and Döhner H: Acute myeloid
leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deschler B and Lübbert M: Acute myeloid
leukemia: Epidemiology and etiology. Cancer. 107:2099–2107. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrara F: Unanswered questions in acute
myeloid leukaemia. Lancet Oncol. 5:443–450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ntziachristos P, Mullenders J, Trimarchi T
and Aifantis I: Mechanisms of epigenetic regulation of leukemia
onset and progression. Adv Immunol. 117:1–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Woods BA and Levine RL: The role of
mutations in epigenetic regulators in myeloid malignancies. Immunol
Rev. 263:22–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han BW and Chen YQ: Potential pathological
and functional links between long noncoding RNAs and hematopoiesis.
Sci Signal. 6:re52013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mer AS, Lindberg J, Nilsson C, Klevebring
D, Wang M, Grönberg H, Lehmann S and Rantalainen M: Expression
levels of long non-coding RNAs are prognostic for AML outcome. J
Hematol Oncol. 11:522018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen ZH, Wang WT, Huang W, Fang K, Sun YM,
Liu SR, Luo XQ and Chen YQ: The lncRNA HOTAIRM1 regulates the
degradation of PML-RARA oncoprotein and myeloid cell
differentiation by enhancing the autophagy pathway. Cell Death
Differ. 24:212–224. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li S, Jin T, Zhang J, Lou H, Yang B, Li Y,
Chen C and Zhang Y: Polymorphisms of TREH, IL4R and CCDC26 genes
associated with risk of glioma. Cancer Epidemiol. 36:283–287. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Hui Y, Li X and Jia Q: Silencing
of lncRNA CCDC26 restrains the growth and migration of glioma cells
in vitro and in vivo via targeting miR-203. Oncol Res.
26:1143–1154. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirano T, Yoshikawa R, Harada H, Harada Y,
Ishida A and Yamazaki T: Long noncoding RNA, CCDC26, controls
myeloid leukemia cell growth through regulation of KIT expression.
Mol Cancer. 14:902015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Radtke I, Mullighan CG, Ishii M, Su X,
Cheng J, Ma J, Ganti R, Cai Z, Goorha S, Pounds SB, et al: Genomic
analysis reveals few genetic alterations in pediatric acute myeloid
leukemia. Proc Natl Acad Sci USA. 106:12944–12949. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin W, Rossin A, Clifford JL and
Gronemeyer H: Co-resistance to retinoic acid and TRAIL by insertion
mutagenesis into RAM. Oncogene. 25:3735–3744. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Swerdlow SH, Campo E, Harris NL, et al:
WHO classifcation of tumours of haematopoietic and lymphoid
tissues. Lyon: IARC; 2008
|
|
16
|
O'Donnell MR, Tallman MS, Abboud CN,
Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre
SE, et al: Acute myeloid Leukemia, Version 3.2017, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
15:926–957. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lei L, Xia S, Liu D, Li X, Feng J, Zhu Y,
Hu J, Xia L, Guo L, Chen F, et al: Genome-wide characterization of
lncRNAs in acute myeloid leukemia. Brief Bioinform. 19:627–635.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heagerty PJ, Lumley T and Pepe MS:
Time-dependent ROC curves for censored survival data and a
diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salerno L, Romeo G, Modica MN, Amata E,
Sorrenti V, Barbagallo I and Pittalà V: Heme oxygenase-1: A new
druggable target in the management of chronic and acute myeloid
leukemia. Eur J Med Chem. 142:163–178. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valk PJ, Verhaak RG, Beijen MA, Erpelinck
CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM,
Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B and Delwel
R: Prognostically useful gene-expression profiles in acute myeloid
leukemia. N Engl J Med. 350:1617–1628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hussaini MO, Mirza AS, Komrokji R, Lancet
J, Padron E and Song J: Genetic landscape of acute myeloid leukemia
interrogated by Next-generation Sequencing: A large cancer center
experience. Cancer Genomics Proteomics. 15:121–126. 2018.PubMed/NCBI
|
|
24
|
Chen L, Wang W, Cao L, Li Z and Wang X:
Long Non-coding RNA CCAT1 Acts as a competing endogenous RNA to
regulate cell growth and differentiation in acute myeloid leukemia.
Mol Cells. 39:330–336. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fernando TR, Contreras JR, Zampini M,
Rodriguez-Malave NI, Alberti MO, Anguiano J, Tran TM, Palanichamy
JK, Gajeton J, Ung NM, et al: The lncRNA CASC15 regulates SOX4
expression in RUNX1-rearranged acute leukemia. Mol Cancer.
16:1262017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gaidzik VI, Teleanu V, Papaemmanuil E,
Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne
CH, Horst HA, et al: RUNX1 mutations in acute myeloid leukemia are
associated with distinct clinico-pathologic and genetic features.
Leukemia. 30:2160–2168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burnett AK, Milligan D, Goldstone A,
Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N,
Hills RK, et al: The impact of dose escalation and resistance
modulation in older patients with acute myeloid leukaemia and high
risk myelodysplastic syndrome: The results of the LRF AML14 trial.
Br J Haematol. 145:318–332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Löwenberg B, Ossenkoppele GJ, van Putten
W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J,
Jongen-Lavrencic M, von Lilienfeld-Toal M, et al: High-dose
daunorubicin in older patients with acute myeloid leukemia. N Engl
J Med. 361:1235–1248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Versluis J, Hazenberg CLE, Passweg JR, van
Putten WL, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J,
Schouten HC, et al: Post-remission treatment with allogeneic stem
cell transplantation in patients aged 60 years and older with acute
myeloid leukaemia: A time-dependent analysis. Lancet Haematol.
2:e427–e436. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cornelissen JJ, Versluis J, Passweg JR,
van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van
Marwijk Kooy M, Wijermans PW, et al: Comparative therapeutic value
of post remission approaches in patients with acute myeloid
leukemia aged 40–60 years. Leukemia. 29:1041–1050. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hira VVV, Van Noorden CJF, Carraway HE,
Maciejewski JP and Molenaar RJ: Novel therapeutic strategies to
target leukemic cells that hijack compartmentalized continuous
hematopoietic stem cell niches. Biochim Biophys Acta Rev Cancer.
1868:183–198. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Behbehani GK, Samusik N, Bjornson ZB,
Fantl WJ, Medeiros BC and Nolan GP: Mass cytometric functional
profiling of acute myeloid leukemia defines Cell-cycle and
immunophenotypic properties that correlate with known responses to
therapy. Cancer Discov. 5:988–1003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kolb HJ, Schattenberg A, Goldman JM,
Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A,
Verdonck L, Niederwieser D, et al: Graft-versus-leukemia effect of
donor lymphocyte transfusions in marrow grafted patients. Blood.
86:2041–2050. 1995.PubMed/NCBI
|
|
34
|
Orti G, Barba P, Fox L, Salamero O, Bosch
F and Valcarcel D: Donor lymphocyte infusions in AML and MDS:
Enhancing the graft-versus-leukemia effect. Exp Hematol. 48:1–11.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dickinson AM, Norden J, Li S, Hromadnikova
I, Schmid C, Schmetzer H and Jochem-Kolb H: Graft-versus-Leukemia
effect following hematopoietic stem cell transplantation for
leukemia. Front Immunol. 8:4962017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Byrd JC, Mrózek K, Dodge RK, Carroll AJ,
Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW and Watson
MS: Pretreatment cytogenetic abnormalities are predictive of
induction success, cumulative incidence of relapse, and overall
survival in adult patients with de novo acute myeloid leukemia:
Results from cancer and leukemia group B (CALGB 8461). Blood.
100:4325–4336. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Slovak ML, Kopecky KJ, Cassileth PA,
Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR,
Rowe JM, et al: Karyotypic analysis predicts outcome of
preremission and postremission therapy in adult acute myeloid
leukemia: A southwest oncology Group/Eastern cooperative oncology
group study. Blood. 96:4075–4083. 2000.PubMed/NCBI
|
|
38
|
Grimwade D, Walker H, Harrison G, Oliver
F, Chatters S, Harrison CJ, Wheatley K, Burnett AK and Goldstone
AH; Medical Research Council Adult Leukemia Working Party, : The
predictive value of hierarchical cytogenetic classification in
older adults with acute myeloid leukemia (AML): Analysis of 1065
patients entered into the United Kingdom medical research council
AML11 trial. Blood. 98:1312–1320. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Grimwade D, Walker H, Oliver F, Wheatley
K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A and
Goldstone A: The importance of diagnostic cytogenetics on outcome
in AML: Analysis of 1,612 patients entered into the MRC AML 10
trial. The Medical Research Council Adult and Children's Leukaemia
Working Parties. Blood. 92:2322–2333. 1998.PubMed/NCBI
|
|
40
|
Döhner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rowe JM and Tallman MS: How I treat acute
myeloid leukemia. Blood. 116:3147–3156. 2010. View Article : Google Scholar : PubMed/NCBI
|
